Earnings ·
Reports Q3 revenue of $1.3 billion and raises full-year growth outlook to 15%-25%
MRNAModerna, Inc.
Moderna reported third-quarter revenue of $1.3 billion, a 29% increase from the prior year period, driven by higher international COVID vaccine sales. GAAP net income was $0.2 billion with diluted EPS of $0.38, compared to a loss in the same quarter last year. The company raised its full-year revenue growth expectation to 15%-25%, up from an outlook of up to 10%, while reducing expected operating expenses by approximately $0.2 billion and increasing the projected ending cash balance to $8.1–$8.3 billion. Moderna also highlighted positive Phase 3 data for intismeran in melanoma and U.S. FDA approval for its influenza vaccine, mFLUSIVA. The company operates as a pioneer in mRNA medicine, developing vaccines and therapeutics across infectious diseases, cancer, and rare diseases.